Nerelimomab

• UNSPSC Description:

  Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis[1][2].

• Target Antigen:

  TNF Receptor

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/nerelimomab.html

• Solubility:

  10 mM in DMSO

• Smiles:

  [Nerelimomab]

• References & Citations:

  [1]Schlag G, et al. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock. 1994 Jul;2(1):10-8; discussion 19-22. |[2]Cohen J, et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996 Sep;24(9):1431-40.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  162774-06-3